Healed Pmma Bone Articles & Analysis
18 news found
BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas. Bone tissue engineering and the research surrounding peptides have expanded significantly over the last few decades. Several peptides have been shown to support and stimulate the bone healing response and have been proposed ...
OSSIO, Inc., an orthopedic fixation technology company, today announced that it has received a contract with Vizient, Inc., making the company’s portfolio of bio-integrative OSSIOfiber products available at negotiated pricing to health care providers in Vizient’s group purchasing organization (GPO) under a three-year contract starting March 1. OSSIO’s contract with Vizient ...
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. The clinical use of this product is expected ...
RevBio, Inc., announced that it has been awarded the opportunity to conduct an in vivo research experiment on the International Space Station U.S. National Laboratory (ISS National Lab). This experiment will examine the biomaterial's osteoconductivity when used in a microgravity environment where bone density and the ability to regenerate new bone tissue is significantly compromised. "Given the ...
Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for the on-going clinical trial, ASPIRE, for P-15L Bone Graft in a single level transforaminal lumbar interbody fusion (TLIF) surgery. “We are pleased to announce ...
Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a ...
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). The FDA’s Breakthrough Device designation is designed to expedite the development and review ...
Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft. Using Synergy’s proprietary BIOSPHERE® Technology, BIOSPHERE® FLEX SP Extremities is a sheet putty composed of innovative spherical bioactive glass granules combined with a porous collagen/sodium hyaluronate ...
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, announced today the completion of enrollment of the ASPIRE study, a pivotal U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study, to evaluate the safety and efficacy of P-15L Bone Graft for use in transforaminal lumbar interbody fusion (TLIF) surgery in patients with ...
Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for patients undergoing ACDF surgery were recently published in ClinicoEconomics and Outcomes Research (July 2021, Volume 2021, Issue 13). In this landmark ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group purchasing agreement for Synthetic Implantable Products with Premier. Effective July 1st, the new agreement allows Premier members, at their discretion, to take advantage of pricing and terms pre-negotiated by Premier for CERAMENT® BONE VOID FILLER. “The awarded ...
FDA’s Breakthrough Device Program helps accelerate patient access to more effective treatments Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to CognitOss, currently in develoment for the treatment of chronic osteomyelitis. The FDA Breakthrough Device ...
Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. “We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, Chief Executive Officer of ...
Cerapedics, a private ortho-biologics company, today announced the Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix, making it the first market to approve the commercial launch of this product. “We are excited to announce Canadian regulatory approval of our next-generation product, based on P15 osteogenic cell-binding peptide , i-FACTOR+ ...
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions private, clinical-stage, ...
Avanti Orthopaedics is an implant company seeking to evolve the art and science of osseous fixation. Born from decades of frontline surgical experience, Avanti Orthopaedics designs and manufactures next generation orthopaedic implants that stand apart. Bidirectionally angled screws, far-cortical locking fixation, variable-angle fixation with PEEK-OPTIMA composite plates and very low profile ...
Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) supplement for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. Cerapedics requested approval for an updated package insert that ...
Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $3.9 million to Ankasa Regenerative Therapeutics for a promising approach to treat a degenerative condition that can cause chronic, progressive back pain. As we get older, the bones, joints and ligaments in our back become weak and less able to hold the spinal column in alignment. As a result, an ...